<DOC>
	<DOCNO>NCT01170117</DOCNO>
	<brief_summary>Anorexia Nervosa ( AN ) serious illness associate substantial morbidity mortality . Weight restoration treatment priority , good treatment need .</brief_summary>
	<brief_title>Olanzapine Versus Placebo Outpatients With Anorexia Nervosa</brief_title>
	<detailed_description>This study 16-week randomize , double-blind , placebo-controlled trial olanzapine adult outpatient AN . 160 individual AN , age &gt; 18 , randomly assign receive olanzapine placebo 16 week together medication management treatment . Primary outcome include weight gain well psychological symptom know associate AN , include obsessionality , mood , anxiety . This project base evidence recently complete 8-week pilot study compare efficacy olanzapine placebo outpatient AN ( PI : Evelyn Attia , MD ) , well recently publish 12-week trial olanzapine v placebo ( Bissada et al , Am J Psychiatry , 2007 ) outpatient treatment olanzapine associate weight improvement , improve psychological status , untoward metabolic effect among low-weight patient . The investigator hypothesize among underweight adult outpatient AN receive olanzapine vs. placebo , together medication management treatment : 1 ) patient AN receive olanzapine gain weight faster rate receive placebo ; 2 ) patient AN receive olanzapine demonstrate great reduction psychological symptom , include obsessionality , mood , anxiety eat disorder symptom , receive placebo .</detailed_description>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Diagnosis Anorexia Nervosa Body Mass Index ( BMI ) 14.0 18.5 kg/m2 Between 1875 year old Patient pursue intensive treatment ( inpatient day treatment ) weight restoration BMI le 18 kg/m2 serum potassium &gt; 2.5 mEq/L Any medical psychiatric problem require medical psychiatric attention , significant metabolic disturbance upon psychiatrist presentation , and/or significant comorbid illness likely benefit propose treatment need specialized treatment noneating disorder symptom . Diabetes mellitus QTc &gt; 480 msec baseline increase QTc &gt; 35 msec since baseline ECG Significant hyperlipidemia ( cholesterol , triglycerides &gt; 1.5 x upper limit normal ) Current diagnosis substance abuse dependence Diagnosis schizophrenia , schizophreniform disorder , bipolar illness ( type I ) Presence movement disorder , tardive dyskinesia History seizure disorder Dementia ( subject age 55 assess MMSE administer psychiatrist ; receive MMSE score &gt; 25 exclude ) Allergy olanzapine Documented treatment 10 mg/day olanzapine x 8 week know inability tolerate olanzapine 10 mg/day Taking psychotropic ( antidepressant , antianxiety , mood stabilizer , antipsychotic ) medication within 4 week prior randomization , stable dose Selective Serotonin Reuptake Inhibitor ( SSRI ) Serotonin/Norepinephrine Reuptake Inhibitor ( SNRI ) , use benzodiazepine nonbenzodiazepine sleep agent . These permissible medication may continue trial use patient period &gt; 4 week unchanged dose without evidence consistent weight gain ( i.e. , &gt; 3 lbs/months ) Taking medication within last four week prior randomization , know affect weight ( e.g. , steroid ) Participation psychotherapeutic intervention associate consistent weight gain ( i.e . &gt; 3 lbs/month ) . ( Subjects may participate study receive stable outpatient psychotherapy 4 week prior randomization long change therapy intensity psychotherapy associate weight gain &gt; 3 lbs previous 4 week . Subjects may also participate recently receive partial weight restoration treatment intensive inpatient day program long document consistently gain weight current treatment set 4 week prior baseline screen . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Eating Disorders</keyword>
	<keyword>Anorexia Nervosa</keyword>
</DOC>